← FDA DRUG APPROVALS

FDA BLA · BLA761497

GARZULYS

Sponsor: EMERGE BIOSCIENCE PTE. LTD.

APPLICATION
BLA761497
TYPE
BLA
ORIGINAL APPROVAL
2026-07-24
LATEST ACTION
2026-07-24
ROUTE
MULTIDOSE, PREFILLED
DOSAGE FORM
VIAL, PEN
MARKETING STATUS
Prescription

Products

GARZULYSPrescription
INSULIN ASPART-FSAN 10ML · VIAL · MULTIDOSE
GARZULYSPrescription
INSULIN ASPART-FSAN 3ML · PEN · PREFILLED

Approval history

2026-07-24UNKNOWN · Original · standardLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Biologics industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →